|
|
MK-7622: A First-in-Class M1 Positive Allosteric Modulator Development CandidateDOI: https://doi.org/10.1021/acsmedchemlett.8b00095 Abstract: Identification of ligands that selectively activate the M1 muscarinic signaling pathway has been sought for decades to treat a range of neurological and cognitive disorders. Herein, we describe the optimization efforts focused on addressing key physicochemical and safety properties, ultimately leading to the clinical candidate MK-7622, a highly selective positive allosteric modulator of the M1 muscarinic receptor that has entered Phase II studies in patients with Alzheimer’s disease
|